Compare Matson Inc (MATX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Matson Inc trades at $204.7 (market cap $6.24B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 21.3× Matson Inc's market cap, and Matson Inc pays a 0.73% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MATX | VRTX | |
|---|---|---|
Market Cap | $6.24B | $132.79B |
Sector | Technology | Health |
52-Week High | $223.55 | $529.65 |
52-Week Low | $88.05 | $376.62 |
Enterprise Value | $6.84B | $126.92B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $206.77, up 0.25% today, with strong technical momentum showing bullish moving averages and support at $205. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $4.27 versus $3.79 expected, and has raised full-year guidance. Valuation remains attractive with a P/E of 14.08 and EV/EBITDA of 7.93, while profitability metrics show a net income margin of 13.41% and ROE of 17.21%.
Outlook remains positive with analyst consensus pointing to 27% upside to $265 price target, supported by continued momentum in China services and resilient consumer demand. Key risks include exposure to Trans-Pacific trade volatility and competitive pressures in shipping markets. The combination of earnings momentum, reasonable valuation, and institutional support suggests favorable risk-reward for investors.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
